Premium
p53 mutant His 175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6
Author(s) -
Runnebaum Ingo B.,
Tong Xiao W.,
Möbus Volker J.,
Kieback Dirk G.,
Rosenthal Heike E.,
Kreienberg Rolf
Publication year - 1994
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(94)00953-8
Subject(s) - missense mutation , fallopian tube , mutant , microbiology and biotechnology , biology , cytoplasm , carcinoma , cell culture , point mutation , cancer research , gene , mutation , genetics , anatomy
Fallopian tube carcinoma is a lethal gynecologic malignancy. Etiologic factors are unknown. No experimental data on molecular alterations exist so far. For an in vitro model, we established the permanent human tubal carcinoma cell line FT‐MZ‐1. The median doubling time was 14 days with 24.2% in S phase. A point missense mutation of the p53 tumor suppressor gene resulting in the His 175 mutant was identified. Aberrant p53 protein accumulated in nucleus and cytoplasm. FT‐MZ‐1 substantially secreted interleukin 6 (Il‐6) coinciding with the inactivation of p53 as a transrepressor on the Il‐6 gene promoter.